Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
ACS Omega ; 2(7): 3616-3631, 2017 Jul 31.
Article in English | MEDLINE | ID: mdl-30023699

ABSTRACT

The cross-linked pentapeptides (2R,7R)-diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((2R,7R)-BVD-74D, (2R,7R)-1) and octanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) (2) as well as the pentapeptide Ac-Tyr-Arg-Leu-Arg-Tyr-amide (3) were previously described as neuropeptide Y Y4 receptor (Y4R) partial agonists. Here, we report on a series of analogues of (2R,7R)-1 and 2 in which Arg2, Leu3, or Arg4 were replaced by the respective aza-amino acids. The replacement of Arg2 in 3 with a carbamoylated arginine building block and the extension of the N-terminus by an additional arginine led to the high-affinity hexapeptide Ac-Arg-Tyr-Nω-[(4-aminobutyl)aminocarbonyl]Arg-Leu-Arg-Tyr-amide (35), which was used as a precursor for a d-amino acid scan. The target compounds were investigated for Y4R functional activity in assays with complementary readouts: aequorin Ca2+ and ß-arrestin 1 or ß-arrestin 2 assays. In contrast to the parent compounds, which are Y4R agonists, several ligands were able to suppress the effect elicited by the endogenous ligand pancreatic polypeptide and therefore represent a novel class of peptide Y4R antagonists.

2.
J Med Chem ; 59(13): 6045-58, 2016 07 14.
Article in English | MEDLINE | ID: mdl-27223253

ABSTRACT

The diastereomeric mixture of d/l-2,7-diaminooctanedioyl-bis(YRLRY-NH2) (BVD-74D, 2) was described in the literature as a high affinity Y4 receptor agonist. Here we report on the synthesis and pharmacological characterization of the pure diastereomers (2R,7R)- and (2S,7S)-2 and a series of homo- and heterodimeric analogues in which octanedioic acid was used as an achiral linker. To investigate the role of the Arg residues, one or two arginines were replaced by Ala. Moreover, N(ω)-(6-aminohexylaminocarbonyl)Arg was introduced as an arginine replacement (17). (2R,7R)-2 was superior to (2S,7S)-2 in binding and functional cellular assays and equipotent with 17. [(3)H]Propionylation of one amino group in the linker of (2R,7R)-2 or at the primary amino group in 17 resulted in high affinity Y4R radioligands ([(3)H]-(2R,7R)-10, [(3)H]18) with subnanomolar Kd values.


Subject(s)
Pancreatic Polypeptide/chemistry , Pancreatic Polypeptide/pharmacology , Protein Precursors/chemistry , Protein Precursors/pharmacology , Receptors, Neuropeptide Y/agonists , Amino Acid Sequence , Animals , CHO Cells , Cell Line, Tumor , Cricetulus , HEK293 Cells , Humans , Pancreatic Polypeptide/chemical synthesis , Protein Precursors/chemical synthesis , Receptors, Neuropeptide Y/metabolism , Stereoisomerism
3.
J Med Chem ; 59(5): 1925-45, 2016 Mar 10.
Article in English | MEDLINE | ID: mdl-26824643

ABSTRACT

Derivatization of biologically active peptides by conjugation with fluorophores or radionuclide-bearing moieties is an effective and commonly used approach to prepare molecular tools and diagnostic agents. Whereas lysine, cysteine, and N-terminal amino acids have been mostly used for peptide conjugation, we describe a new, widely applicable approach to peptide conjugation based on the nonclassical bioisosteric replacement of the guanidine group in arginine by a functionalized carbamoylguanidine moiety. Four arginine-containing peptide receptor ligands (angiotensin II, neurotensin(8-13), an analogue of the C-terminal pentapeptide of neuropeptide Y, and a neuropeptide FF analogue) were subject of this proof-of-concept study. The N(ω)-carbamoylated arginines, bearing spacers with a terminal amino group, were incorporated into the peptides by standard Fmoc solid phase peptide synthesis. The synthesized chemically stable peptide derivatives showed high receptor affinities with Ki values in the low nanomolar range, even when bulky fluorophores had been attached. Two new tritiated tracers for angiotensin and neurotensin receptors are described.


Subject(s)
Angiotensin II/pharmacology , Arginine/analogs & derivatives , Neuropeptide Y/pharmacology , Neurotensin/pharmacology , Oligopeptides/pharmacology , Peptide Fragments/pharmacology , Receptors, Angiotensin/metabolism , Receptors, Neuropeptide/metabolism , Receptors, Neurotensin/metabolism , Angiotensin II/chemistry , Arginine/chemistry , Cells, Cultured , Dose-Response Relationship, Drug , Humans , Ligands , Molecular Structure , Neuropeptide Y/chemistry , Neurotensin/chemistry , Oligopeptides/chemistry , Peptide Fragments/chemistry , Receptors, Neuropeptide/agonists , Receptors, Neurotensin/antagonists & inhibitors , Structure-Activity Relationship
4.
J Med Chem ; 58(22): 8834-49, 2015 Nov 25.
Article in English | MEDLINE | ID: mdl-26466164

ABSTRACT

Analogues of the argininamide-type NPY Y1 receptor (Y1R) antagonist BIBP3226, bearing carbamoyl moieties at the guanidine group, revealed subnanomolar Ki values and caused depression of the maximal response to NPY (calcium assay) by up to 90% in a concentration- and time-dependent manner, suggesting insurmountable antagonism. To gain insight into the mechanism of binding of the synthesized compounds, a tritiated antagonist, (R)-N(α)-diphenylacetyl-N(ω)-[2-([2,3-(3)H]propionylamino)ethyl]aminocarbonyl-(4-hydroxybenzyl)arginin-amide ([(3)H]UR-MK299, [(3)H]38), was prepared. [(3)H]38 revealed a dissociation constant in the picomolar range (Kd 0.044 nM, SK-N-MC cells) and very high Y1R selectivity. Apart from superior affinity, a considerably lower target off-rate (t1/2 95 min) was characteristic of [(3)H]38 compared to that of the higher homologue containing a tetramethylene instead of an ethylene spacer (t1/2 3 min, Kd 2.0 nM). Y1R binding of [(3)H]38 was fully reversible and fully displaceable by nonpeptide antagonists and the agonist pNPY. Therefore, the insurmountable antagonism observed in the functional assay has to be attributed to the extended target-residence time, a phenomenon of relevance in drug research beyond the NPY receptor field.


Subject(s)
Arginine/analogs & derivatives , Arginine/chemistry , Diphenylacetic Acids/pharmacokinetics , Radiopharmaceuticals/pharmacokinetics , Receptors, Neuropeptide Y/antagonists & inhibitors , Amides , Animals , Arginine/pharmacokinetics , Binding, Competitive , CHO Cells , Cell Line , Cricetinae , Cricetulus , Fluorescent Dyes , Fura-2 , Half-Life , Humans , Isotope Labeling , Molecular Probes , Neuropeptide Y/analogs & derivatives , Neuropeptide Y/pharmacology , Receptors, Neuropeptide/drug effects , Receptors, Neuropeptide Y/administration & dosage , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...